Table 2.
Variable | Baseline | 9 month (clinical trial) |
18 month (9-month post- Clinical trial) |
27 month (18-month post clinical Trial) |
---|---|---|---|---|
Control (n=39) | ||||
SBP | 150.1 ±9.6 | 132.0 ±15.1* | 143.3 ±17.5** | 141.2 ±15.8** |
DBP | 85.4 ±10.7 | 79.1 ±11.7 | 75.7 ±9.5 | 77.1 ±11.3 |
BP control (%)† | 0 | 48.7%# | 30.8%## | 35.9%§ |
Intervention (n=65) | ||||
SBP | 152.5 ±9.5 | 124.5 ±10.7* | 131.0 ±12.2** | 131.3 ±13.0** |
DBP | 85.5 ±12.2 | 75.2 ±10.2 | 77.1 ±8.7 | 76.3 ±11.7 |
BP control (%)* | 0 | 78.5%# | 53.9%## | 55.3%§ |
BP control defined as <130/80 mm Hg for patients with diabetes or chronic kidney disease and <140/90 for non-diabetic patients.
Between group differences:
p = 0.0038;
p < 0.001;
p=0.0017,
p=0.02,
p=0.05